Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1358

Sort by

Sort Order Select

Journal Articles

Basophilic myeloblasts: a clue for CML blast phase

Huifei Liu

Blood (2021) 137 (20): 2852.

https://doi.org/10.1182/blood.2021011420

Published: 2021

Journal Articles

Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML

Huan-You Wang, Dimitrios Tzachanis

Blood (2020) 136 (9): 1112.

https://doi.org/10.1182/blood.2020006326

Published: 2020

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML

Naranie Shanmuganathan, MBBS FRACP FRCPA, Daniel Thomson, PhD BSc, Carol Wadham, PhD, Verity A Saunders, Nur Hezrin Shahrin, PhD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Hamish S Scott, PhD FFSc (RCPA), Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Andreas Schreiber, Susan Branford, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 662.

https://doi.org/10.1182/blood-2019-123180

Published: 2019

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Landscape of TP53 Mutations in MPN

Noushin Farnoud, PhD, Christopher Famulare, MS, Elli Papaemmanuil, PhD, Erin McGovern, BA, Juan Medina, MS, Juan E. Arango Ossa, BS, Raajit K. Rampal, MD PhD, Bing Li, MD, Ross L. Levine, MD, John Mascarenhas, MD, Rona Singer Weinberg, PhD, Minal A Patel, MPH, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1681.

https://doi.org/10.1182/blood-2019-132014

Published: 2019

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters

Jayachandran PK, MD MRCP, DM, Trivadi S Ganesan, MD FRCP, PhD, Nikita Mehra, MD DM, Krishnarathinam Kannan, MD DM, Manikandan Dhanushkodi, MD DM, Venkatraman Radhakrishnan, MD DM, Arun Kumar Rajan, MD DM, Joshi Archit Girishchandra, MD DM, Gangothri Selvarajan, MD DM, Parathan Karunakaran, MD DM, Tenali Gnana Sagar, MD DM

Blood (2019) 134 (Supplement_1): 1654.

https://doi.org/10.1182/blood-2019-125998

Published: 2019

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

The Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding and Represents a Druggable Target

Christophe Desterke, PhD, Sarah Pagliaro, Pharm D, Patricia Hugues, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 1632.

https://doi.org/10.1182/blood-2019-124796

Published: 2019

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan

Shohei Mizuno, MD PhD, Masamitsu Yanada, Koji Kawamura, Shingo Yano, MD PhD, Masayoshi Masuko, MD, Naoyuki Uchida, MD PhD, Yukiyasu Ozawa, MD PhD, Koji Iwato, Kazuteru Ohashi, MD PhD, Kazuhiro Ikegame, MD PhD, Sung-Won Kim, MD PhD, Masatsugu Tanaka, MD, Tetsuya Eto, MD PhD, Yoshinobu Kanda, MD PhD, Takahiro Fukuda, Yoshiko Atsuta, MD PhD, Akiyoshi Takami, MD

Blood (2019) 134 (Supplement_1): 2045.

https://doi.org/10.1182/blood-2019-122801

Published: 2019

Journal Articles

Distance Does Not Matter: Excellent Survival Outcomes for Leukemia Patients in Rural Appalachia

Krista Isaac, DO,MS, Daniel R Reed, MD, Raj Piyush Desai, MS, Eli Williams, PhD, Rajesh Balkrishnan, PhD, Michael K Keng, MD, Karen K. Ballen, MD

Blood (2019) 134 (Supplement_1): 4784.

https://doi.org/10.1182/blood-2019-125829

Published: 2019

Journal Articles

GATA2 Zinc Finger Mutations Influence Erythroid Differentiation and Chemotherapy Response

Georg Leubolt, MSc, Enric Redondo Monte, MSc, BSc, Anja Wilding, MSc, Paul Kerbs, MSc, Monica Cusan, MD, Johannes Bagnoli, Wolfgang Enard, PhD, Wolfgang Hiddemann, MD PhD, Christian Wichmann, MD, Gunnar Schotta, PhD, Philipp A. Greif, MD PD

Blood (2019) 134 (Supplement_1): 1459.

https://doi.org/10.1182/blood-2019-128218

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation

Jenny M. Ho, MD, Jessie J.F. Medeiros, BSc, Michelle Chan-Seng-Yue, Lauren Hummel, BSc, Andrea Arruda, Amanda Mitchell, PhD, Caroline J McNamara, MBBS, James A Kennedy, MD PhD, Anne Tierens, MD PhD, Dawn Maze, MDFRCPC,MSc, Hubert Tsui, MD PhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 1676.

https://doi.org/10.1182/blood-2019-130923

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, MD PhD, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 2967.

https://doi.org/10.1182/blood-2019-129397

Published: 2019

Journal Articles

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Zafar Iqbal, BSc, MSc, PhD, Muhammad Absar, BSc, MSc, PhD, Abid Jameel, MD PhD, Tanveer Akhtar, PhD, Sulman Basit, PhDMSc, Aamer Mahmood, PhD, Aamir Aleem, MBBS FRCP, Nawaf Alanazi, MBBS FRCPC, Ullah Anhar, Naila Batool Khalid, Sibtain Afzal, Jamil Amjad Hashmi, Afia M Akram, PhD, Khushnooda Ramzan, PhD, Mahmood Rasool, Muhammad Hasaan Aziz, Muhammad Farooq Sabar, PhD, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid, PhD

Blood (2019) 134 (Supplement_1): 2939.

https://doi.org/10.1182/blood-2019-125518

Published: 2019

NARROW

Basophilic myeloblasts: a clue for CML blast phase

Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Landscape of TP53 Mutations in MPN

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

The Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding and Represents a Druggable Target

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan

Distance Does Not Matter: Excellent Survival Outcomes for Leukemia Patients in Rural Appalachia

GATA2 Zinc Finger Mutations Influence Erythroid Differentiation and Chemotherapy Response

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only